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Aim: High-flow nasal cannula (HFNC) therapy provides non-invasive respiratory support for infant 
bronchiolitis and its use has increased following good clinical experiences. This national study 
describes HFNC use in Finland during a severe respiratory syncytial virus (RSV) epidemic. 
Methods: A questionnaire on using HFNC for infant bronchiolitis during the 2015-2016 RSV 
epidemic was sent to the head physicians of 18 Finnish children`s hospitals providing inpatient 
care for infants: 17 hospitals answered, covering 77.5% of the infants born in Finland in 2015.  
Results: Most (85%) HFNC was given on paediatric wards. The mean incidence for bronchiolitis 
treated with HFNC  in infants under the age of one in 15/17 hospitals was 3.8 per 1,000 per year 
(range 1.4-8.1). One excluded hospital did not supply the relevant data and one supplied a figure 
of 34.1 due to different treatment policy. Instructions on how to start and wean HFNC therapy 
were present in 71% and 61% of the hospitals, respectively, weighted to the population. Providing 
weaning instructions was associated with shorter weaning times.  
Conclusion: HFNC was actively used for infants with bronchiolitis, with no substantial over-use. 
Randomised controlled studies are needed before any evidence-based guidelines can be 
constructed for using HFNC in infant bronchiolitis.  
 
Key notes:  
x This questionnaire-based study evaluated high-flow nasal cannula treatment for infant 
bronchiolitis in Finland during the 2015-2016 respiratory syncytial virus epidemic.  
x Responses were received from 17 children’s hospitals and the mean incidence of HFNC 
treatments was  3.8 per 1,000 per year.  
x Instructions on how to start HFNC were provided more often (71%) than how to wean 
(61%) and providing weaning advice was associated with shorter weaning times.   
 
Key words: Bronchiolitis, High-flow nasal cannula, Respiratory syncytial virus epidemic, Treatment 
instructions, Weaning instructions 
 
Abbreviations: HFNC, high-flow nasal cannula; PICU, paediatric intensive care unit; RCT, 
randomised controlled trial; RSV, respiratory syncytial virus; SpO2, oxygen saturation; FiO2, fraction 




Bronchiolitis is the leading infectious cause of hospitalisation in infancy (1). In European countries 
it is usually defined as an acute respiratory infection with breathing difficulties in infants under 12 
months of age (2) and the diagnosis is clinical, based on typical signs and symptoms (3). As there is 
no widely accepted consensus on the treatment of infants with bronchiolitis, the therapy tends to 
focus on maintaining oxygenation and hydration (4).  
 
High-flow nasal cannula (HFNC) therapy is a relatively new approach to treating, and even 
preventing, hypoxia in respiratory diseases (5). It involves administering a heated and humidified 
mixture of oxygen and air via a nasal cannula at a flow rate of more than three litres a minute, 
which reduces the dead space and  causes continuous distending pressure in the airways (5,6).  
 
Physiological studies have shown that when bronchiolitis patients were treated with HFNC, oxygen 
saturation improved and the work of breathing, respiratory rate and heart rate decreased (6,7). 
HFNC seems to be well tolerated in infants with bronchiolitis (8), but the research-based clinical 
evidence on its effectiveness is insufficient (5, 8). Some studies have compared infants with 
bronchiolitis who were treated with HFNC to historical controls who were treated in the same 
hospital with standard low-flow oxygen administration. The results of these studies were positive, 
in line with subjective clinical experience (9,10). 
 
In an Italian semi-randomised pilot study, infants hospitalised for bronchiolitis at less than 12 
months of age, and treated with HFNC, presented with lower clinical severity scores, shorter 
oxygen administration times and shorter hospitalisation stays than controls treated with standard 
low-flow oxygen (11). An Australian randomised controlled trial (RCT) published in 2017 comprised 
202 infants with moderate bronchiolitis who were less than 24 months of age and had oxygen 
saturation (SpO2) levels of 90-94%. Half were randomised to HFNC and the other half to standard 
low-flow therapy. The groups did not differ in terms of weaning time or the need for intensive 
care, but treatment failures were less common in the HFNC group (14%) than in the controls (33%) 
and 60% of the controls that failed to respond were successfully treated with HFNC (12). Thus, 
HFNC therapy may have a role to play as rescue therapy for infant bronchiolitis in order to avoid 
high-cost intensive care. 
  
Five RCT studies are currently being carried out on HFNC therapy in bronchiolitis to our 
knowledge: one large study  in Australia and New Zealand (13) and four other studies that have 
recorded their protocols in the Clinical Trials Register. 
 
Until now, no evidence-based guidelines have been constructed for HFNC in infant  bronchiolitis, 
simply due to the lack of such evidence. There is a risk that the non-controlled use of HFNC will 
expand, with varying indications and protocols that are only based on the experiences of single 
teams or even single doctors.  The aim of this national questionnaire study was to evaluate the use 
of HFNC for infant bronchiolitis in children’s hospitals in Finland and the period we chose was 






MATERIAL AND METHODS  
 
In this descriptive study, the data were collected by a questionnaire that was specially written for 
this study and included  both quantitative and open qualitative questions. The questionnaire, 
which covered the indications and practices of HFNC treatment in infants with bronchiolitis, was 
sent to the head physicians of the paediatric departments of 18 Finnish hospitals that provided 
inpatient care for young children. Of those, three were university hospitals, 13 were central 
hospitals and two were large regional hospitals working in close connection with a tertiary 
university hospital. We received completed questionnaires from 17 hospitals that were primarily 
responsible for 43,202 (77.5%) of the 55,759 infants born in Finland 2015, according to official 
Government statistics. The hospital that did not respond was one of the 13 central  hospitals. 
 
The questionnaire consisted of questions on the HFNC treatment provided for infants hopitalised 
for bronchiolitis below the age of 12 months between 1 November 2015 to 31 May 2016, when 
there was severe nationwide epidemic caused by the RSV. The collected data included the 
numbers of bronchiolitis patients treated with HFNC and whether the hospital provided its staff 
with instructions on how to initiate, wean and to cease HFNC therapy. We also asked respondents 
about the indications for HFNC treatment, including the SpO2 threshold, the starting, maximum 
and end settings for gas flows and the SpO2 oxygen saturations during HFNC. There were also 
questions about whether nasogastric tubes were routinely used, and about the indications and 
practices for fluid therapy. The questionnaire also requested details on how many HFNC 
treatments were carried out in the paediatric intensive care unit (PICU) or other intensive care 
units and how many were carried out on the paediatric ward. The attending doctors were asked to 
describe, in their own words, what indications they used to start, wean and cease HFNC 
treatment, including the gas flows they used, the fractions of inspired oxygen (FiO2) and the 
starting and target SpO2 levels of the patients. Answers to the open qualitative questions were 
catogorised by the authors as quantitative variables in the analyses.  
 
We did not send the questionnaires to two university hospitals, Tampere University Hospital and 
Oulu University Hospital, because both these hospitals were involved in an ongoing RCT on the 
HFNC treatment of infants with bronchiolitis, which started in 2016 during the RSV epidemic 
(Clinical Trials Register, No NCT02737280). These two hospitals treated bronchiolitis patients 
according to the RCT study protocol. In short, infants who were less than six months old and had 
been hospitalised for bronchiolitis were eligible to be included in the study and the indication for 
enrollment was an SpO2 below or equal to 91% with room air without the need for mechanical 
ventilation. The starting flow for HFNC treatment depended on the child’s weight: 5L/min for 3-
4kg, 6L/min for 4-7kg and 8L/min for 8-10kg. The FiO2 was adjusted to keep the SpO2 at 92-95%. 
HFNC treatment was ceased when the FiO2 had been 21% for two hours and the flow had been 5-
8L/min for the same amount of time. 
 
The analyses were performed with SPSS version 24 (SPSS Inc, Chicago, Illinois, USA). We used 
descriptive statistics and the results were presented as unweighted and weighted means and 
medians and ranges. Each hospital was given a weighted index, depending on the number of 
infants born in the catchment area of the hospital in 2015. The Mann-Whitney U test was used in 
the statistical analyses. The surveillance period was seven months, including the RSV epidemic, 
and we did not make any corrections when we calculated the incidences, which were expressed as 
per year. 
 
RESULTS   
 
The age-specific mean incidence of bronchiolitis treated with HFNC between 1 November 2015 
and 31 May 2016 in infants under the age of one in 15/17 hospitals was 3.8 per 1,000 per year, 
with a range of 1.3-8.7 and 95% confidence interval (95% CI) of 2.4-5.2. We excluded one  central 
hospital that did not supply the relevant data and one small central hospital that supplied an age-
specific incidence of 34.1 per 1,000 due to long distances to intensive care facilities as this outlier 
would have artificially skewed the overall mean (Table S1). In the latter hospital, all infants with 
bronchiolitis who needed oxygen were treated with HFNC. Most (86.5%) of the HFNC treatments 
were given on the paediatric wards and only 13.5% were provided in the PICU or other intensive 
care units.  
 
We found that 10 hospitals provided instructions on how to start HFNC, which equated to a  
weighted percentage of 71.1%,  and seven of those hospitals told staff how to wean patients off 
and cease HFNC, which was a weighted percentage of 60.6%. The other seven hospitals (28.9%) 
did not provide instructions on starting or weaning HFNC (Table 1). Nasogastric tubes were 
routinely inserted in nine hospitals, which equated to a weighted percentage 40.1% and short-
term fluids were admistered intravenously in five hospitals, which was a weighted percentage of  
30.2% (Table 1). The comparison of crude and weighted percentages suggests that instructions, 
especially those for weaning off and ceasing HFNC, were more likely to be present in large 
hospitals, but the routine insertion of nasogastric tubes was more common in small hospitals 
(Table 1).  
 
The presence of instructions for starting HFNC was not significantly associated with the number of 
infants in the area or the number of HFNC treatments provided by the hospital (Data not shown). 
However, the presence of instructions for weaning off HFNC were significantly associated with the 
number of infants in the area (medians, 2,580 if present versus 2,257 if not present, p=0.019) and 
the number of HFNC treatments provided by the hospital (medians, 17 if present versus 11 if not 
present, p=0.012). This meant that large hospitals treated more patients with HFNC were more 
likely to also provide instructions for weaning off and ceasing HFNC. 
 
The most important indication for HFNC was reduced SpO2  and the limit varied between 90% or 
less and 95% or less, with a weighted median of 91%. The target SpO2 during HFNC varied 
between 90% or more and 95% or more, with a weighted median of 91%. The starting FiO2 varied 
from 21% to 50%, with a weighted median of 21%. The starting flow and maximum flow during  
HFNC were expressed as interpolated for an infant weighing 10kg and the weighted medians were 
10 L/min (4-20 L/min) and 20 L/min (7-50 L/min), respectively.  
 
The weaning protocols varied substantially (Table 2). The minimum weaning time, expressed as a 
weighted median, ranged from 8 to 20 hours. The minimum flow rate when the clinical staff were 
ready to end HFNC ranged from 4L/min to 5L/min and the FiO2 was 30%, with all figures expressed 
as weighted medians. The weaning times of HFNC were shorter, and the flow rates and FiO2 were 







There were three main results to emerge from the present questionnaire-based  study on clinical 
practices for  HFNC treatment of infants with bronchiolitis in Finnish children`s hospitals during the 
RSV epidemic in winter 2015-2016. First, the mean incidence of HFNC treatments was 3.8 per 
1,000 per year in infants under 12 month old in the general population, which means that around 
0.4% of the age cohort was treated with HFNC in hospital during that epidemic. Second, the 
instructions on when and how to start HFNC therapy for bronchiolitis were present in 71% of the 
hospitals, but only 61% of the hospitals provided instructions on when and how to wean the 
bronchiolitis patients off HFNC therapy. These percentages were weighted, and were higher than 
the crude percentages, which means that large hospitals were more likely to provide instructions 
than small hospitals. The presence of weaning instructions were associated with a shorter weaning 
time. Third, the great majority (85%) of HFNC treatments were successfully given on the paediatric 
wards. 
 
A 2014 paper, published before the RSV epidemic covered by this study, quantified the incidence 
of bronchiolitis in infants admitted to the emergency room at less than six months of age as 37 per 
1,000 in Finland and 70% of cases were treated in hospital, which means that the incidence of 
hospitalisations was 26 per 1,000 per year (14).  In the present study, the mean incidence of 
bronchiolitis treated with HFNC at less than 12 months of age was 3.8 per 1,000 per year. No data 
are available on the incidence of bronchiolitis hospitalisations during the winter 2015-2016 
epidemic, which the present study covers. If we apply the incidence figures presented above, we 
can estimate that around 15% of infants hospitalised for bronchiolitis were treated with HFNC,  
which does not suggest any substantial overuse of HFNC. In one hospital, all bronchiolitis patients 
who needed oxygen support were treated with HFNC if there was a device free. That hospital was 
small, had limited paediatric intensive care facilities and was situated a long way from the tertiary 
hospital. As it was an obvious statistical outlier, it was not included in the mean incidence quoted 
above as that would have artifically skewed the figure.  
The indications for starting HFNC treatment did not substantially differ between the Finnish 
children`s hospitals, despite the fact that some did not provide formal instructions. The limits of 
hypoxia that were treated with oxygen support varied between an SpO2 of 90% to 95%, but similar 
variations can be seen in the international bronchiolitis guidelines (3). In the Finnish bronchiolitis 
guidelines, the lowest SpO2 that did not require oxygen administration was set at 92% (15), which 
was close to the weighted median (91%) observed in the present study.  
 
The starting flow rates were in accordance with the instructions given by the manufacturers of the 
devices, but during HFNC treatment the hospitals reported surprisingly high maximal flows of 20L 
or even higher. Distending airway pressure depended on the size of the patient, the flow rate and 
the diameter of the nasal cannula compared to the nares (8,16). There have not been any studies 
that compared flows above 10L/min and distending airway pressure in infants (5), but higher flows 
up to 50L/min have been used in older children and adults (17,18). The lack of studies, together 
with the case reports on serious air leakage in children treated with HFNC (19), indicate that 
caution is needed with flows that are higher than 10L/min in infants.  
 
The average weaning time varied from three to 48 hours in those 12 children`s hospitals, which 
reported it.  The detailed instructions for weaning were present in seven of them. The weaning 
time was shorter and the flow and FiO2 just before the HFNC ended was higher, if the instruction 
for weaning were available. It was evident that there was a risk of using  unnecessarily slow 
weaning protocols, since most of the paediatric experience has been using HFNC  with neonates, 
who need to be weaned slowly, for example by reducing the flow rate by 0.5L/min per hour, when 
the maximum rates are not needed anymore (5). In contrast, in infants with bronchiolitis, the 
reduction rate can be  1.0L/min per hour or even a more rapid reduction (5). 
 
The recommended flow when doctors were ready to end HFNC treatment varied between 2L/min 
and 8L/min. When the flow is 2L/min or less it is not defined as high-flow treatment anymore and 
the use of the HFNC device does not offer any benefits over standard oxygen administration (20). 
A flow of 2-3L/min is needed to produce distending pressure (21,22). In addition, there is evidence 
that the high flow itself, without any additional oxygen administration, improves oxygen uptake 
and reduces respiratory work (15). HFNC use may be harmful if the flow is less than 2L/min and  
there is no air leak through the nares (22). 
 
Increasing evidence from retrospective studies suggests that HFNC treatment is safe with no 
substantial risk of complications (8) and prospective pilot studies have reported that treatment 
can be carried out on the pediatric ward (10,23). In the only RCT study published so far on the 
effectiveness of HFNC treatment, Kepreotes et al reported that only four minor adverse events 
occurred in 101 infants with bronchiolitis and none of them led to them being withdrawn from the 
trial (12).  On the other hand, the risk of adverse effects can be higher, if there is bronchial 
obstruction caused by smooth muscle contraction, as in wheezy bronchitis or asthma (19,24). 
 
The main impact of HFNC therapy may the reduction of PICU treatment, which is much more 
expensive than treatment on the ward (9,10,25). As seen in the only RCT study, HFNC may have a 
a special role as rescue therapy to prevent or shorten intensive care (12) or to reduce the need to 
transfer patients to tertiary hospitals (13). We found that 85% of the HFNC treatments in the 
present study were carried out on paediatric wards and the doctors did not report any substantial 
complications.  
 
Nasogastric tubes were routinely used for HFNC treated infants in more than half of the hospitals 
we surveyed. Interestingly, the weighted percentage was lower than the crude percentage, which 
means that this routine was common in small hospitals. Nasogastric tubes were not routinely used 
in the only RCT on HFNC in infants with bronchiolitis and the authors did not report cases with 
substantial abdominal distension (12).  
 
The present study had some limitations. It is difficult to say how well the answers given by the 
head doctors, or by the senior doctors who were responsible for bronchiolitis treatment in the 
hospitals, reflected the real practices in the departments. On the other hand, our aim was to 
evaluate whether there were instructions on HFNC treatment for bronchiolitis and, if present, 
what those recommendations were.  Our aim was not  to evaluate how the patients were actually 
treated. The strength of the study is that we received completed questionnaires from all but one 
of the eligible hospitals and the answers covered more than 77% of all infants born in Finland in 
2015 when expressed as a weighted percentage.  
 
Conclusions   
 
The mean incidence of HFNC treatment was 3.8 per 1,000 in infants who were less than 12 months 
of age, which suggests that HFNC was actively used, but not overused, in bronchiolitis treatment in 
Finland. We found that 71% of  hospitals provided instructions how to start treatment, but only 
61% provided instructions for weaning. Instructions are particularly needed for weaning to avoid 
unnecessary long treatment times. Well-designed randomised controlled studies on HFNC 





The authors are grateful to the 17 paediatricians responsible for bronchiolitis treatment, who 




1. Smyth R, Openshaw P. Bronchiolitis. Review. Lancet 2006; 368: 312-22. 
2. Mecklin M, Hesselmar B, Qvist E, Wennergren G, Korppi M. Diagnosis and treatment of 
bronchiolitis in Finnish and Swedish children's hospitals. Acta Paediatr 2014;103:946-50. 
3. Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. Lancet 2017;389:211-24. 
4. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. 
American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, 
and prevention of bronchiolitis. Pediatrics 2014;134: e1474-502 . 
5. Hutchings FA, Hilliard TN, Davis PJ. Heated humidified high-flow nasal cannula therapy in 
children. Arch Dis Cild 2015;100:571-5.           
6. Hough JL, Pham TM, Schibler A. Physiologic effect of high-flow nasal cannula in infants with 
bronchiolitis. Pediatr Crit Care Med 2014;15:e214-9.  
7. Sinha IP, McBride AK, Smith R, Fernandes RM. CPAP and high-flow nasal cannula oxygen in 
bronchiolitis. Chest 2015;148:810-23. 
8. Mikalsen IB, Davis P, Øymar K. High flow nasal cannula in children: a literature review. 
Scand J Trauma Resusc Emerg Med 2016;24:93.  
9. Riese J, Fierce J, Riese A, Alverson B.  Effect of hospital-wide high-flow nasal cannula 
protocol on clinical outcomes and resource utilisation of bronchiolitis patients admitted to 
the PICU. Hosp Pediatr 2015;5:613-7. 
10.  Heikkilä P, Forma L, Korppi M. High-flow oxygen therapy is more cost-effective for 
bronchiolitis than standard treatment-A decision-tree analysis  Pediatr Pulmonol 
2016;51:1393-402. 
11. Milani GP, Plebani AM, Arturi E, Brusa D, Esposito S, Dell'Era L, et al. Using a high-flow nasal 
cannula provided superior results to low-flow oxygen delivery in moderate to severe 
bronchiolitis. Acta Paediatr 2016;105:e368-72.  
12. Kepreotes E, Whitehead B, Attia J, Oldmeadow C, Collison A, Searles A, Goddard B, et al. 
High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for 
moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial. 
Lancet 2017; 389:930-39. 
13. Franklin D, Dalziel S, Schlapbach LJ, Babl FE, Oakley E, Craig SS, et al. Early high flow nasal 
cannula therapy in bronchiolitis, a prospective randomised control trial (protocol): A 
Paediatric Acute Respiratory Intervention Study (PARIS). BMC Pediatr 2015;15:183.  
14. Pruikkonen H, Uhari M, Dunder T, Pokka T, Renko M. Infants under 6 months with 
bronchiolitis are most likely to need major medical interventions in the 5 days after onset. 
Acta Paediatr 2014;103:1089-93.  
15. Tapiainen T, Aittoniemi J, Immonen J, Jylkkä H, Meinander T, Nuolivirta K, et al. Finnish 
guidelines for the treatment of laryngitis, wheezing bronchitis and bronchiolitis in children. 
Acta Paediatr 2016;105:44-9.  
16. Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy: mechanisms of 
action. Respir Med 2009;103:1400-5.  
17. Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through 
nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015;372:2185–96.  
18. Wing R, James C, Maranda LS, Armsby CC. Use of high-flow nasal cannula support in the 
emergency department reduces the need for intubation in pediatric acute respiratory 
insufficiency. Pediatr Emerg Care 2012;28:1117–23. 
19. Hegde S, Prodhan P. Serious air leak syndrome complicating high-flow nasal cannula 
therapy: a report of 3 cases. Pediatrics 2013;131:e939-44.  
20. Rubin S, Ghuman A, Deakers T, Khemani R, Ross P, Newth CJ. Effort of breathing in children 
receiving high-flow nasal cannula. Pediatr Crit Care Med 2014;15:1–6. 
21. Spence KL, Murphy D, Kilian C, McGonigle R, Kilani RA. High-flow nasal cannula as a device 
to provide continuous positive airway pressure in infants. J Perinatol 2007;27:772-5.  
22. Milési C, Baleine J, Matecki S, Durand S, Combes C, Novais AR, et al. Is treatment with a 
high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. Intensive 
Care Med 2013;39:1088-94. 
23. Mayfield S, Bogossian F, O’Malley L, Schibler A. High-flow nasal cannula oxygen therapy for 
infants with bronciolitis: pilot study. J Paediatr Child Health 2014;50:373-8. 
24. Long E, Babl FE, Duke T. Is there a role for humidified heated high-flow nasal cannula 
therapy in paediatric emergency departments? Emerg Med J 2016;33:386–9. 
25. Heikkilä P, Forma L, Korppi M. Hospitalisation costs for infant bronchiolitis are up to 20 




Table 1. Presence of instructions for starting HFNC, for weaning off HFNC, and on the use of 
nasogastric tubes and intravenous routes, presented as weighted percentages with 95% 
confidence intervals.  
Instructions Number of hospitals Percentage Weighted 
percentage*  
Instructions present 
for starting HFNC 
10  58.8 % 71.1 %  
Instructions present 
for weaning off HFNC 
7  41.2 % 60.6 % 
 
Nasogastric tube 
routinely used during 
HFNC 





6  35.3% 30.2 % 
 
*Weighted for the number of infants in the catchment area of the hospital. 
 
Table 2.  Weaning time, gas flow and inspired oxygen fraction limits for ending HFNC in infants 
with bronchiolitis.  
Weaning times, gas flows and inspired 
oxygen fractions (n = number of 
hospitals) 
Medians weighted for numbers 
of infants in the area (range) 
Weaning time (hours), minimum  
(n=12) 
8 (3 – 48) 1 
Weaning time (hours), maximum  
(n=12) 
20 (5 – 48) 2 
Ready to end flow (L/min) minimum 
(n=13) 
4 (2 – 6) 3 
Ready to end flow (L/min)  maximum  
(n=13) 
5 (2 – 8) 4 
Ready to end FiO2 (%)  
(n=16) 
30 (21 – 40) 5 
FiO2 inspared oxygen fraction  
1 6(3-12) if instructions present versus 24(4-48) if not present (p<0.001) 
2 8(5-24) if instructions present versus 24(4-48) if not present (p<0.001)  
3 5(2-6) if instructions present versus 3(2-5) if not present (p<0.001) 
4  5(3-6) if instructions present versus 4(2-6) if not present (p<0.001) 
5 40(21-40) if instructions present versus 21(21-25) if not present (p<0.001) 
  
SUPPLEMENTARY MATERIAL 
Table S1. Basic data on the hospital districts included in the study, including the incidence of HFNC 
treatments per 1,000 infants aged less than 12 months in the hospital district.  
  








Number of infants 
with bronchiolitis 
treatedwith HFNC (1 
November 2015 to 
31 May 2016) 
Incidence of HFNC 
treatments per 
1,000 infants aged 




Central Hospital  2,058    0.048 5 2.43 
Mikkeli Central 
Hospital 1,063    0.025 5 4.70 
Children's Hospital 
Helsinki (plus 
Porvoo hospital) 11,329    0.257 40 3.53 
Jorvi Hospital (plus 
Lohja hospital) 4,889    0.112 28 5.73 
Hyvinkää Hospital 1,858    0.043 5 2.69 
Central Hospital of 
Kainuu 586    0.014 20 34.13 
Central Hospital of 
Tavastia 1,560    0.036 2 1.28 
Central Hospital of 
Keski-Pohjanmaa 876    0.020 - - 
Central Finland 
Central Hospital 2,583    0.060 14 5.42 
Kymenlaakso 
Central Hospital 1,431    0.033 5 3.49 
Lapland Central 
Hospital 1,058    0.024 8 7.56 
North Karelia 
Central Hospital 1,507    0.035 3 1.99 
Kuopio University 
Hospital 2,294    0.053 20 8.71 
Päijänne-Tavastia 
Central Hospital 1,887    0.044 6 3.18 
Satakunta Central 
Hospital 2,012    0.047 8 43.98 
Vaasa Central 
Hospital 1,889    0.044 4 2.12 
Turku University 
Hospital (plus Salo 
hospital) 4,615    0.107 25 5.42 
The annual incidences are calculated from the numbers of bronchiolitis patients hospitalised 
during the study period without any corrections.The mean age-specific incidence was 3.8 per 
1,000 per year. The central hospital of Kainuu was not included in the calculation, because the 
indications for HFNC treatment differed from other hospitals. The data were not received from the 
Central Hospital of Keski-Pohjanmaa.  
 
 
